financetom
Business
financetom
/
Business
/
Coty's Preliminary Q1 Results: Slower Sales Growth, Reaccelerates Cost Savings & More
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Coty's Preliminary Q1 Results: Slower Sales Growth, Reaccelerates Cost Savings & More
Oct 17, 2024 12:47 PM

Coty Inc. ( COTY ) shares are trading lower today. On Monday, the company reported preliminary first-quarter results, with sales growing around 4%-5% on a like-for-like basis slightly below earlier estimate of 6%.

The company says Prestige fragrances are thriving due to increased volume and price, while mass beauty faces slower growth driven by declining unit demand.

However, Coty ( COTY ) has achieved revenue growth in other key markets and remains relatively unaffected by the challenges in China due to its limited exposure there.

The company expects the first quarter adjusted EBITDA to be flat to moderately lower year-over-year.

Coty ( COTY ) reports that lower-than-expected order patterns in the latter half of the first quarter, coupled with investments in high-ROI initiatives, fixed cost timing, and the profit impact from divesting the Lacoste license, are the contributing factors.

Cost Saving Initiatives: Coty ( COTY ) plans to re-accelerate its cost reduction initiatives due to uncertain demand and cautious retailer behavior. It aims to achieve savings exceeding the initial FY25 target of $75 million.

Q2 & FY24 Outlook: Given ongoing caution from retailers and a slowing U.S. market, Coty ( COTY ) now expects moderate second-quarter LFL sales growth.

The company anticipates growth acceleration in the second half, aided by easier comparisons, improved alignment between sell-in and sell-out, strong product launches, and selective distribution expansion.

Coty ( COTY ) reiterated that FY25 adjusted EBITDA will grow 9%-11% year over year, supported by ongoing sales growth, gross margin expansion, and cost savings.

Coty ( COTY ) plans to release first quarter results on November 6, 2024.

Price Action: COTY ( COTY ) shares are down 10.1% at $8.24 at the last check Tuesday.

Read Next:

Tech YouTuber MKBHD Says ‘I’ll Shave My Head On Camera’ If Elon Musk’s Tesla Delivers Cybercab Before 2027 As Robotaxi Timeline Faces Skepticism

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Starwood Property Trust Prices $500 Million Private Notes Offering
Starwood Property Trust Prices $500 Million Private Notes Offering
Dec 18, 2024
04:26 AM EST, 12/18/2024 (MT Newswires) -- Starwood Property Trust ( STWD ) said late Tuesday it priced a private offering of $500 million of its 6.5% unsecured senior notes due 2030 at 100% of the principal amount. The offering was upsized from $400 million and is expected to settle on Dec. 27. The company said it plans to use...
UniCredit ups Commerzbank stake as BPM bid faces hurdles
UniCredit ups Commerzbank stake as BPM bid faces hurdles
Dec 18, 2024
* UniCredit ups Commerzbank stake via derivatives to 28% * Process ongoing to seek authorisation for stake of up to 29.9% * UniCredit also trying to buy Italian rival BPM * BPM's market price well above UniCredit bid's price (Adds comments from Commerzbank in paragraph 4, details in 8-10) MILAN, Dec 18 (Reuters) - UniCredit has raised its stake in...
Caesars Entertainment Opens Caesars Virginia Resort, Casino
Caesars Entertainment Opens Caesars Virginia Resort, Casino
Dec 18, 2024
04:22 AM EST, 12/18/2024 (MT Newswires) -- Caesars Entertainment ( CZR ) said late Tuesday it has opened its Caesars Virginia resort and casino in the city of Danville. The 587,000-square-foot resort includes gambling space and a 320-room hotel, among other facilities. ...
Novo Nordisk's Ozempic faces EU review for potential eye disease connection
Novo Nordisk's Ozempic faces EU review for potential eye disease connection
Dec 18, 2024
COPENHAGEN, Dec 18 (Reuters) - The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes drug Ozempic to a rare eye disease. The studies published earlier this week had found Ozempic significantly increases the risk of type 2 diabetes patients developing NAION (non-arteritic anterior ischemic optic neuropathy), more than doubling the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved